AAO 2023: Promising outcomes from IOL implantation following radial keratotomy

News
Article

Data from the study, presented at the 2023 American Academy of Ophthalmology meeting in San Francisco, support the implantation of the LAL in eyes that had undergone a previous RK

An intraocular lens, balanced on a finger. Image credit: ©Nino – stock.adobe.com

Investigators studied the effect of light-adjustable lens in outcomes for patients with previous RK. Image credit: ©Nino – stock.adobe.com

Tanner J. Ferguson, MD, and colleagues from Vance Thompson Vision in Sioux Falls, SD, reported favorable outcomes regarding the visual and refractive outcomes with the Light-Adjustable Lens (LAL) (RxSight) in patients who had previously undergone radial keratotomies (RKs) with implantation of this lens after cataract surgery.

The case series included patients with history of 4-cut, 8-cut, and 16-cut RKs. The authors highlight the value of the adjustable nature of the LAL in patients with prior RK, a population that characteristically has reduced accuracy of IOL power calculations.

Ferguson reported the results at the 2023 American Academy of Ophthalmology meeting in San Francisco.

The investigators undertook a retrospective study of patients with a previous RK implanted with the LAL. In this series, they included eyes with a plano target (0.00 diopter [D]) before their final lock-in and excluded eyes with concomitant ocular pathologies that limited the corrected distance visual acuity (CDVA). The primary outcome measures included the percentage of eyes achieving a monocular uncorrected DVA (UDVA) of 20/x or better and the % of eyes within ±0.25, ±0.5, and ±1.00 D of target.

Ferguson and colleagues included 44 eyes from 34 patients in the study. They reported the following results: the monocular UDVA was 20/20 or better in 66% of eyes, 20/25 or better in 75% of eyes, and 20/30 or better in 95% of eyes 1 month after lock-in following a series of light adjustments. With emmetropia as the target, 73% of eyes were within ±0.5 D, and 93% were within ±1.00 D of that target. The MRSE was 0.4 ± 0.4 D. The mean time following implantation of the LALs to the final lock-in procedure was 9.2 ± 3.1 weeks.

The authors concluded, “The visual and refractive outcomes in this study support the implantation of the LAL in eyes that had undergone a previous RK. The postoperative adjustability of the LAL affords improved outcomes for cataract surgery in these eyes.”

Ferguson also added, “These outcomes highlight the improved visual and refractive outcomes using the LAL in post-RK eyes, but patient selection and counseling remain important in these patients as the pre-existing higher-order aberrations may limit image quality and it is important to closely evaluate the degree of irregular astigmatism before surgery.”

In addition to Ferguson, the other co-authors included Marlee Jones, BS; Daniel Terveen, MD; Brent A. Kramer, MD; Vance M. Thompson, MD; and John P. Berdahl, MD

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.